Renal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis
The Oncologist · 06.08.2026 · 31 (9)
DOI: 10.1093/oncolo/oyag283 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 21.07.2026. Verfasst von Sanmei Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
With life expectancies of patients with chronic myeloid leukemia (CML) now approaching those of the general population under tyrosine kinase inhibitor (TKI) therapy, understanding long-term treatment-related toxicities becomes paramount. Although imatinib’s nephrotoxic potential is established, the renal safety profiles of second-generation TKIs—dasatinib, nilotinib, and flumatinib—remain incompletely characterized.
Methods
This single-center retrospective study analyzed renal function trajectories in 348 patients with CML receiving first-line imatinib, dasatinib, nilotinib, or flumatinib. Renal function was assessed using serum creatinine and estimated glomerular filtration rate (eGFR). Mixed-effects models incorporating treatment group, time, and their interaction as fixed effects were used to formally compare eGFR trajectories across treatment groups. Chronic renal adverse events and acute kidney injury were also evaluated.
Results
Formal comparison of eGFR trajectories across treatment groups revealed a significant time × treatment interaction, indicating differential renal function changes among the 4 TKIs. Significant serum creatinine elevation and eGFR decline were observed in imatinib and flumatinib groups, contrasting with stable creatinine and divergent eGFR patterns in dasatinib (slight increase) and nilotinib (decline) groups. The incidence of chronic renal adverse events varied substantially across cohorts—12.3% (imatinib), 2.6% (nilotinib), 4.3% (dasatinib), and 9.6% (flumatinib). Notably, among 3 documented acute kidney injury cases, all occurred during flumatinib treatment. Furthermore, treatment-free remission achievement did not confer significant renal function recovery, suggesting potential irreversibility of established renal damage.
Conclusion
TKIs exhibit differential renal safety profiles, underscoring the critical importance of individualized TKI selection based on baseline renal status and implementation of rigorous renal monitoring protocols throughout treatment duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China.
- Department of Nephrology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China.
Zitieren
APA
Wang, S., Lei, Y., Liu, S., Zhang, B., Zhao, X., Qiao, C., Hong, M., Qian, S., Fan, L., & Zhu, Y. (2026). Renal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag283
Vancouver
Wang S, Lei Y, Liu S, Zhang B, Zhao X, Qiao C, et al. Renal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag283
BibTeX
@article{Wang2026,
author = {Wang, Sanmei and Lei, Yutian and Liu, Simeng and Zhang, Bo and Zhao, Xiaoli and Qiao, Chun and Hong, Ming and Qian, Sixuan and Fan, Lei and Zhu, Yu},
title = {Renal dysfunction in patients with CML on long-term first-line TKI therapy: a single-center analysis},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {9},
doi = {10.1093/oncolo/oyag283}
}
EUVIMED